Semaglutide, a synthetic analog of glucagon-like peptide-1 (GLP-1), has garnered attention for its intriguing properties and potential implications in various r ...

For patients with diabetes, exposure to GLP-1 RAs is associated with an increased risk for incident neovascular AMD development.

Among older patients with diabetes, glucagon-like peptide 1 receptor agonists were associated with an increased risk for ...

Biodexa Pharmaceuticals ( ($BDRX) ) just unveiled an announcement. On June 4, 2025, Biodexa Pharmaceuticals announced the recruitment of the first ...

Increased consumption of phytosterols reduced the risk for CVD and type 2 diabetes, a study presented at the annual NUTRITION ...

Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes Biodexa Pharmaceuticals PLC ...

This recent study introduces a non–insulin-specific version of the Diabetes Eating Problem Survey–Revised tool that screens ...

GLP-1 RAs are associated with a significant decrease in apnea-hypopnea index among patients with moderate to severe OSA and without diabetes.

Tirzepatide is the first dual-target therapy that activates both GIP and GLP-1 receptors, helping manage blood sugar levels ...

Eli Lilly is partnering with Camurus, a company with technology that extends how long an injectable drug lasts in the body, ...

Growth Hormone-Releasing Peptide-2 (GHRP-2) is a synthetic hexapeptide that has garnered significant attention in the ...

USV, an Indian multinational healthcare company and holds the 1st position by prescriptions in the Oral Anti-Diabetic and ...